Skip to main content

Non-Invasive Neuromodulation of the Central Nervous System Opportunities and Challenges: Workshop Summary (2015) / Chapter Skim
Currently Skimming:

10 The Business Environment
Pages 71-74

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 71...
... INDUSTRY PERSPECTIVES Given that current treatment options for psychiatric illnesses such as depression are suboptimal, increased recognition that the underlying mechanisms of disease involve neural networks is needed, according to several participants. Particularly given the demonstrated responsiveness of these networks to electrical stimulation, along with a changing reimbursement landscape, there is considerable interest in industry to develop new neuromodulation devices, according to Mark Demitrack.
Read the entire page →
From page 72...
... . A reflection of its emerging acceptance as a treatment option is the incorporation of TMS therapy as recommended treatment consideration when initial pharmacotherapy has failed in various international practice guidelines (see, for example, the American Psychiatric Association, the World Federation of Societies for Biological Psychiatry, and the Royal Australia and New Zealand College of Psychiatrists)
Read the entire page →
From page 73...
... Despite excitement in the field, Jaffe said there has been a less than 70 percent drop in the amount of funding for early-stage medical device companies since the peak in 2008 (Norris, 2013) ; although, there has been an increase in funding for devices that monitor chronic illnesses and a person's overall health (Laird Wireless Connectivity Blog, 2015; RnR
Read the entire page →
From page 74...
... . The reason is the significant capital requirements and the long development time frame required for investors to see a return on their investment, which Jaffe blamed primarily on issues of regulation and reimbursement.
Read the entire page →

Key Terms

  • treatment options
  • initial pharmacotherapy
  • device companies
  • tms therapy
  • development time

  • attractive path
  • reported feeling
  • lfms remain
  • human clinical
  • world federation

  • innovation ecosystem
  • spectroscopic imaging
  • currently sells
  • connectivity blog
  • generating financial

  • chronic disease
  • zealand college
  • attack chronic
  • effective antidepressant
  • atric association

  • systemic treatment
  • neuroelectrics currently
  • transcranial current
  • increased understanding
  • tdcs delivers

  • financial returns
  • sion reported
  • affect human
  • medical innovation
  • jaffe calls


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.